Clinical Trial Update: Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude [Phase 4]

View source ↗

Summary

A Phase 4 study is evaluating whether Cavir is non-inferior to Baraclude in HBeAg-positive chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Baraclude (entecavir)
• Cavir

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Chronic Hepatitis B | Phase 4 | Status: UNKNOWN